292 related articles for article (PubMed ID: 12839285)
1. Acute intermittent porphyria in childhood: a population-based study.
Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
[TBL] [Abstract][Full Text] [Related]
2. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
Sardh E; Harper P; Andersson DE; Floderus Y
Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnostics of acute intermittent porphyria.
Kauppinen R
Expert Rev Mol Diagn; 2004 Mar; 4(2):243-9. PubMed ID: 14995910
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
Marsden JT; Rees DC
J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
[TBL] [Abstract][Full Text] [Related]
5. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
[TBL] [Abstract][Full Text] [Related]
6. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
[TBL] [Abstract][Full Text] [Related]
7. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
Aarsand AK; Petersen PH; Sandberg S
Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
[TBL] [Abstract][Full Text] [Related]
8. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
Kauppinen R; von und zu Fraunberg M
Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
[TBL] [Abstract][Full Text] [Related]
9. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
[TBL] [Abstract][Full Text] [Related]
10. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden.
Innala E; Andersson C
J Intern Med; 2011 May; 269(5):538-45. PubMed ID: 21198994
[TBL] [Abstract][Full Text] [Related]
11. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry.
Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490
[TBL] [Abstract][Full Text] [Related]
12. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.
Sardh E; Andersson DE; Henrichson A; Harper P
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004
[TBL] [Abstract][Full Text] [Related]
13. Awareness is the name of the game: clinical and biochemical evaluation of a case of a girl diagnosed with acute intermittent porphyria associated with autism.
Luder AS; Mamet R; Farbstein I; Schoenfeld N
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):19-22. PubMed ID: 19267997
[TBL] [Abstract][Full Text] [Related]
14. [Diabetic metabolism protective in severe acute intermittent porphyria].
Andersson C; Lithner F
Lakartidningen; 2001 Dec; 98(51-52):5874-6. PubMed ID: 11806263
[TBL] [Abstract][Full Text] [Related]
15. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
[TBL] [Abstract][Full Text] [Related]
16. [Anesthetic management of a patient with a history of acute intermittent porphyria and an elevation of urinary porphobilinogen].
Hiraki T; Oishi K; Kano T
Masui; 2001 Aug; 50(8):882-5. PubMed ID: 11554022
[TBL] [Abstract][Full Text] [Related]
17. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
18. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.
Prabahar MR; Manorajan R; Sathiyakumar D; Soundararajan P; Jayakumar M
Hemodial Int; 2008 Jan; 12(1):34-8. PubMed ID: 18271838
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria.
Marcos J; Ibañez M; Ventura R; Segura J; To-Figueras J; Pozo OJ
J Mass Spectrom; 2015 Jul; 50(7):929-37. PubMed ID: 26349648
[TBL] [Abstract][Full Text] [Related]
20. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
